Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Comp…
Die MorphoSys AG (FSE: MOR; NASDAQ: MOR) gibt heute bekannt, dass ihr Lizenzpartner Roche (SIX: RO, ROG; OTCQX: RHHBY) e…
Die MorphoSys AG (FSE: MOR; NASDAQ: MOR) gab heute bekannt, dass ihrem Lizenzpartner Roche (SIX: RO, ROG; OTCQX: RHHBY)…
Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today th…
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM C…
Textile materials technology innovator HeiQ (LSE:HEIQ) has become a publicly listed company on the London Stock Exchange…
GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies I…
. Celgene Secures Exclusive Options to Three Immatics TCR-T Targets Immatics to Receive $75 Million Upfront Payment an…
Wie GOLDINVEST.de schon verschiedentlich berichtet hat, ist der kanadische Yukon derzeit eine der „heißesten“ Regionen w…
Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option un…